Find all our interviews in our Youtube channel
President of the International Society for Nuclear Capture Therapy.
University of Granada, Spain
Secretary and treasurer of the International Society for Nuclear Capture Therapy.
University of Pavia, Italy
Vice-President of the International Society for Neutron Capture Therapy.
University of Tsukuba, Japan
Member of the Board of Councilors of the ISNCT.
University Hospital Birmingham, U.K
Technical Chair – Chemistry, Executive Board of the ISNCT.
Tokyo Institute of Technology, Japan
Expert on veterinary application of BNCT.
Comisión Nacional de Energía Atómica and CONICET, Argentina
Co-winner of the 2021 Hatanaka award.
National Tsing-Hua University, Hsinchu, Taiwan
Osaka Medical and Pharmaceutical University, Japan & Nacional Research Center (CNRS), France
Manager at Neuboron Medtech.
University of Aeronautics and Astronautics, Nanjing, China
Nuclear physicist at the International Atomic Energy Agency
IAEA, Vienna, Austria
Head of Department at the Comisión Nacional de Energía Atómica CNEA, Buenos Aires, Argentina
Kent Riley Award winners 2022 and 2015
Neuboron Therapy System, China & National Institute for Nuclear Physics, Italy
Other BNCT related Interviews
Dr. Yi-Wei Chen
Education is the main method to popularize BNCT, a powerful special cancer treatment
Accelerator-based BNCT will be chosen as a primary therapy for early stage cancer
Prof. Hiroshi Fukuda
The 50-year history of boron neutron capture therapy
Dr. Amanda E. Schwint
Enjoy every step of the way and admit “there are always more questions than answers”
Prof. Akira Matsumura
the accelerator-based clinical trial of BNCT for melanoma will be started in 2019
The use of a suitable boron drug in BNCT will be beneficial to treat liver cancer patients
Dr. Tatsuhiko Sato
A new model for estimating therapeutic effect of BNCT using the PHITS code
Prof. Jun Hatazawa
Boron neutron capture therapy (BNCT)—a star that needs the joint of multi-discipline knowledge
Prof. Rolf F. Barth
The future of BNCT will depend on the clinical trials of accelerator-based BNCT